Fondaparinux (Arixtra), a new anticoagulant.
D000925:Anticoagulants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000077425:Fondaparinux; D006470:Hemorrhage / Q000139:chemically induced; D007275:Injections, Intravenous; D011134:Polysaccharides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control; D020246:Venous Thrombosis / Q000517:prevention & control
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D011134:Polysaccharides; D000077425:Fondaparinux